Clinical Trial Update: CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas [Phase 1]

View source ↗

Summary

ClinicalTrials.gov reports on a Phase 1 study of CC-8490 in patients with recurrent or refractory high-grade gliomas. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• CC-8490

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED